SAT1

Diamine acetyltransferase 1 · P21673 · SAT1 on Sugi Atlas →

3,645 patent compounds predicted against SAT1, 2,382 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bis(Ethyl)Norspermine (SCHEMBL429527)	0.65	3/20
SCHEMBL5932612	0.65	3/20
Hydrochloric Acid (SCHEMBL431600)	0.63	3/20
SCHEMBL4157457	0.62	3/20
SCHEMBL4167237	0.62	3/20
SCHEMBL4171429	0.62	3/20
Bis(Ethyl)Norspermine (SCHEMBL5548459)	0.62	3/20
SCHEMBL6899291	0.62	3/20
Bis(Ethyl)Spermine (SCHEMBL7092466)	0.62	3/20
SCHEMBL2148646	0.62	3/20
SCHEMBL2529872	0.59	3/20
SCHEMBL2640195	0.59	3/20
Diethylhomospermine (SCHEMBL426504)	0.57	3/20
SCHEMBL429223	0.57	3/20
Hydrochloric Acid (SCHEMBL429529)	0.57	3/20
Hydrochloric Acid (SCHEMBL431350)	0.57	3/20
SCHEMBL997030	0.56	3/20
SCHEMBL5172702	0.56	3/20
Hydrochloric Acid (SCHEMBL3877574)	0.55	3/20
Hydrochloric Acid (SCHEMBL6663700)	0.55	3/20

Clinical trials — most relevant to SAT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)	PHASE3	COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects	PHASE1	COMPLETED
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients.	nan	COMPLETED
Optimal Approach for Analysis of Case-Control Genetic Association Studies	nan	COMPLETED
Study to Investigate Adipocyte Cell and Lipid Turnover in Obese Adolescents	nan	COMPLETED
Histamine Pharmacogenetics in Children With Atopic Dermatitis	nan	COMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Molecular and Histological Characteristics of Serrated Lesions of the Colon	nan	ACTIVE_NOT_RECRUITING
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Family Resilience Initiative Research Program	nan	UNKNOWN
Prevalence of DAO (diamino Oxidase) Deficiency in Newborns	nan	COMPLETED
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus	nan	ACTIVE_NOT_RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart	nan	UNKNOWN
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan	nan	ENROLLING_BY_INVITATION
Genetic Variants and Regulation of Specialized Pro-resolving Mediator	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SAT1 binder may also engage these)

Protein	Name	Similarity
P49431	—	1.000	P49431 →
Q9JHW6	—	1.000	Q9JHW6 →
Q01612	—	1.000	Q01612 →
Q28999	—	1.000	Q28999 →
Q3T0Q0	—	1.000	Q3T0Q0 →
P48026	—	1.000	P48026 →
Q8AXL1	—	0.999	Q8AXL1 →
P39979	—	0.977	P39979 →
P79081	—	0.977	P79081 →
Q06592	—	0.977	Q06592 →
P43577	—	0.975	P43577 →
Q7PCJ9	—	0.972	Q7PCJ9 →
Q6P8J2	—	0.971	Q6P8J2 →
Q7PCJ8	—	0.971	Q7PCJ8 →
Q9I8W5	—	0.970	Q9I8W5 →
Q66KL0	—	0.969	Q66KL0 →
Q66I74	—	0.969	Q66I74 →
Q9T079	—	0.968	Q9T079 →
Q6WAU1	—	0.968	Q6WAU1 →
Q9UT60	—	0.968	Q9UT60 →
P66835	—	0.968	P66835 →
B5MCN3	—	0.968	B5MCN3 →
P0A952	—	0.968	P0A952 →
O22898	—	0.967	O22898 →
Q9VZD2	—	0.967	Q9VZD2 →
O93806	—	0.967	O93806 →
Q9FIN1	—	0.966	Q9FIN1 →
A4UHT7	—	0.966	A4UHT7 →
A0A397HK53	—	0.966	A0A397HK53 →
Q5D013	—	0.966	Q5D013 →